Chronic Neuropathic Pain Market: Industry Analysis, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight| Algiax Pharmaceuticals, Centrexion Therapeutics, Kineta and Others.
Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aβ, Aδ and C fibres) and central neurons, and affects 7–10% of the general population.
DelveInsight's "Chronic
Neuropathic Pain Market Insights, Epidemiology, and Market
Forecast-2030" report delivers an in-depth understanding of the
Chronic Neuropathic Pain, historical and forecasted epidemiology as well as the
Chronic Neuropathic Pain market trends in the United States, EU5 (Germany,
Spain, Italy, France, and United Kingdom) and Japan.
Some facts of Chronic
Neuropathic Pain Market:
·
Chronic Neuropathic Pain is more frequent in
women (8% vs. 5.7% in men) and in patients >50 years of age (8.9% vs. 5.6%
in those <49 years of age), and most commonly affects the lower back and
lower limbs, neck and upper limbs.
·
According to an article by Melillo (2020),
published on the American Journal of Managed Care, in France the prevalence of
chronic neuropathic pain is around 6.9%.
·
Of the emerging therapies, the most anticipated
product to get launched is AP-325. Apart from this, several other molecules are
in early clinical stage or completed clinical studies such as CNTX-6016,
KCP-506, HPI201, and others.
·
As per the article by Yu et al. (2020), titled
“Neuromodulation Management of Chronic Neuropathic Pain in the Central Nervous
System,” chronic neuropathic pain is a widespread condition that affects 7–8%
of the total population.
·
The United States has the highest percentage of
prevalent diagnosed and treated patients (2018-2030)
·
Neuropathic pain underlies an estimated 30–65%
of the activity seen at hospital pain clinics.
View Report: https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Request for a Sample
Page: https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
Chronic
Neuropathic Pain Market Report
Highlights:
- The
report covers the descriptive overview of Chronic Neuropathic Pain,
explaining its causes, signs and symptoms, pathophysiology, diagnosis and
currently available therapies
- Comprehensive
insight has been provided into the Chronic Neuropathic Pain epidemiology
and treatment in the 7MM
- Additionally,
an all-inclusive account of both the current and emerging therapies for Chronic
Neuropathic Pain are provided, along with the assessment of new therapies,
which will have an impact on the current treatment landscape
- A
detailed review of Chronic Neuropathic Pain market; historical and
forecasted is included in the report, covering drug outreach in the 7MM
- The
report provides an edge while developing business strategies, by
understanding trends shaping and driving the global Chronic Neuropathic
Pain market
View Report: https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Request for a Sample
Page: https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
Central Neuropathic Pain results include multiple sclerosis (MS), spinal cord
injury (SCI), central post stroke pain, and Parkinson disease.
Neuropathic pain
is usually caused by chronic, progressive nerve disease, and it can also occur as
the result of injury or infection. Chronic neuropathic pain, can flare up at
any time without an obvious pain-inducing event or factor. Acute neuropathic
pain which is uncommon, can occur as well.
Multiple causes
of neuropathic pain have been described and its incidence is likely to increase
owing to the ageing global population, increased incidence of diabetes mellitus
and improved survival from cancer after chemotherapy. Neuropathic pain may
result from disorders of the peripheral nervous system or the central nervous
system (brain and spinal cord). Thus, neuropathic pain may be divided into
peripheral neuropathic pain, central neuropathic pain, or mixed (peripheral and
central) neuropathic pain.
View Report: https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Request for a Sample
Page: https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
Key Chronic
Neuropathic Pain Companies
covered:
·
Algiax Pharmaceuticals
·
Centrexion Therapeutics
·
Kineta
·
MedinCell
·
And Many Others
Chronic
Neuropathic Pain Drugs covered:
·
AP-325
·
CNTX-6016
·
α9α10 nAChR (KCP-506)
·
mdv-NVA
·
And Many Others
Request for a Sample
Page: https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
Table of Contents:
1. Key Insights
2. Executive Summary
of Hemophilia B
3. Competitive
Intelligence Analysis for Hemophilia B
4. Hemophilia B:
Market Overview at a Glance
5. Hemophilia B:
Disease Background and Overview
6. Patient Journey
7. Hemophilia B
Epidemiology and Patient Population
8. Treatment
Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of
Hemophilia B Treatment
11. Marketed
Products
12. Emerging
Therapies
13. Hemophilia B:
Seven Major Market Analysis
14. Attribute
analysis
15. 7MM: Market
Outlook
16. Access and
Reimbursement Overview of Hemophilia B
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight
Capabilities
22. Disclaimer
View Report: https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Request for Detailed
TOC: https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
Related Reports:
·
Intrahepatic
Cholangiocarcinoma Market
·
Chemotherapy
Induced Diarrhea Market
·
Immunologic
Deficiency Syndrome Market
·
Binge
Eating Disorder Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market
Research firm focused exclusively on life sciences. It supports Pharma
companies by providing end to end comprehensive solutions to improve their
performance. Get hassle-free access to all the healthcare and pharma
market research reports through our subscription-based platform PharmDelve.
Comments
Post a Comment